Carbimazole |
Formulary
|
Tablets 5mg, 20mg Manufacturer advises of the importance of recognising bone marrow suppression induced by carbimazole and the need to stop treatment promptly. Warn patients that if a sore throat develops, in the first 6-8 weeks of therapy they should stop treatment and seek medical advice. |
MHRA Drug Safety Update Feb 2019: Carbimazole: increased risk of congenital malformations; strengthened advice on contraception MHRA Drug Safety Update Feb 2019: Carbimazole: risk of acute pancreatitis |
|
Iodine containing preparations non-acute use |
Formulary
|
LSCMMG: Iodine Containing Preparations |
|